MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK et al. Expert Opin Ther Pat. 2017 Jun 19:1-20. doi: 10.1080/13543776.2017.1339688. [Epub ahead of print].

Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV et al. Hum Vaccin Immunother. 2017 Jun 12:1-7. doi: 10.1080/21645515.2017.1327487. [Epub ahead of print].

Sending CAR T Cells After Multiple Myeloma.
[No authors listed]. Cancer Discov. 2017 Jun 6. doi: 10.1158/2159-8290.CD-NB2017-088. [Epub ahead of print].

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.
Franssen LE et al. Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.118. [Epub ahead of print].

Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Tian C et al. Ann Hematol. 2017 Aug;96(8):1407-1410. doi: 10.1007/s00277-017-3029-3. Epub 2017 Jun 2.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.
Pianko MJ et al. Leuk Lymphoma. 2017 May 30:1-4. doi: 10.1080/10428194.2017.1320713. [Epub ahead of print].